Current options for the treatment of Paget's disease of the bone

Open Access Rheumatology: Research and Reviews

Volumn 1, Issue 1, 2009, Pages 107-120

  Merlotti, Daniela ^a   Gennari, Luigi ^a   Martini, Giuseppe ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Aminobisphosphonates; Bisphosphonates; Bone remodeling; Paget's disease of bone

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; NERIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUPUNCTURE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRITIS; BONE MALFORMATION; BONE PAIN; BONE RADIOGRAPHY; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; HEARING IMPAIRMENT; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; JAW OSTEONECROSIS; MINERALIZATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NERVE COMPRESSION; NERVE STIMULATION; NEUROLOGICAL COMPLICATION; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; PAGET BONE DISEASE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; WALKING AID;

EID: 77953431224     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/oarrr.s4504     Document Type: Review

References (115)

1. Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1877;60:37-63.
2. Altman RD. Paget's disease of bone. In Disorders of Bone and Mineral Metabolism. Coe FL, Favus MJ, editors. Raven Press; New York; 1991. p. 1027-1064.
3. Barker DJ. The epidemiology of Paget disease. Metab Bone Dis Relat Res. 1981;3:231-233.
4. Detheridge FM, Guyer PB, Barker DJ. European distribution of Paget's disease of bone. Br Med J. 1982;285:1005-1008.
5. Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the Epidemiology of Paget's Disease of Bone. J Bone Miner Res. 2006;21:3-8.
6. van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget disease of bone in England and Wales. J Bone Miner Res. 2002;17:465-471.
7. Barker DJ, Chamberlain AT, Guyer PB, Gardner MJ. Paget disease of bone: the Lancashire focus. Br Med J. 1980;280:1105-1107.
8. Cooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D. The epidemiology of Paget disease in Britain: is the prevalence decreasing? J Bone Miner Res. 1999;14:192-197.
9. Cundy T, McAnulty K, Wattie D, Gamble G, Rutland M, Ibbertson HK. Evidence for secular change in Paget disease. Bone. 1997;20:69-71.
10. Roodman GD, Windle JJ. Paget's disease of bone. J Clin Invest. 2005;115:200-208.
11. Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J. p62 ubiquitin bindingassociated domain mediated the receptor activator of nuclear factorkappa B ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone. Am J Pathol. 2006;169: 503-514.
12. Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappa B signalling and Paget's disease of bone with a severe phenotype. J Bone Miner Res. 2006;21:1136-1145.
13. Merlotti D, Gennari L, Galli B, et al. Characteristics and familial aggregation of Paget's disease of bone in Italy. J Bone Miner Res. 2005;20:1356-1364.
14. Poncelet A. The neurologic complications of Paget's disease. J Bone Miner Res. 1999;14:88-91.
15. Ooi CG, Fraser WD. Paget's disease of bone. Postgrad Med. 1997; 73:69-74.
16. Strickenberger SA, Schulman SP, Hutchins GM. Association of Paget's disease of bone with calcific aortic valve disease. Am J Med. 1987;82:953-956.
17. Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer. 1986;57:1442-1449.
18. Jacobs TP, Michelsen J, Polay JS, D Adamo AC, Canfield RE. Giant cell tumor in Paget's disease of bone: familial and geographic clustering. Cancer. 1979;44:742-747.
19. Siris ES, Feldman F. Natural history of untreated Paget's disease of the tibia. J Bone Miner Res. 1997;12:691-692.
20. Meunier PJ, Vignot E. Therapeutic strategy in Paget disease of bone. Bone. 1995;17:489S-491S.
21. Bickerstaff DR, Douglas DL, Burke PH, O Doherty DP, Kanis JA. Improvement in facial deformity of Paget's disease treated with diphosphonates. J Bone Joint Surg Br. 1990;72:132-136.
22. Murdin LM, Yeoh LH. Hearing loss treated with pamidronate. J R Soc Med. 2005;98:272-274.
23. Selby PL, Davie MWJ, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone. 2002;31:366-373.
24. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget's disease of bone: implications for treatment and review of current therapies. J Bone Miner Res. 2006;21:94-97.
25. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol. 1985;3:155-157.
26. Papapoulos SE, Eekhoff EM, Zwinderman AH. Acquired resistance to bisphosphonates in Paget's disease of bone. J Bone Miner Res. 2006;21:88-91.
27. Russell G. Bisphosphonates from bench to bedside. Ann NY Acad Sci. 2006;1068:367-401.
28. Canfield RE, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget disease of bone. J Clin Endocrinol Metab. 1977;44:96-106.
29. Siris ES, Jacobs TP, Canfield RE. Paget's disease of bone. Bull N Y Acad Med. 1980;56:285-304.
30. Siris E, Canfield R, Jacobs T, Stoddart K, Spector T. Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res. 1981;3:301-308.
31. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, doubleblind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995;38:851-885.
32. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med. 1997;336:558-566.
33. McClung MR, Tou CPK, Goldstein NH, Picot C. Tiludronate therapy for Paget's disease of bone. Bone. 1995;17:493S-496S.
34. Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994;47:945-982.
35. Delmas PD, Chapuy MC, Vignon E, et al. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab. 1982;54:837-844.
36. Douglas DL, Duckworth T, Kanis JA, et al. Biochemical and clinical responses to dichloromethylene diphosphonate (CI2MDP) in Paget's disease of bone. Arthritis Rheum. 1980;23:1185-1192.
37. Meunier PJ, Alexaudre C, Edourd C, et al. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet. 1979;2:489-492.
38. Gray RES, Yates APJ, Preston CJ, et al. Duration of effects of oral diphosphonate therapy in Paget's disease of bone. Q J Med. 1987;245:755-767.
39. Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA. Duration of response with oral clodronate in Paget's disease of bone. Bone. 1996;18:185-190.
40. Siris ES, Weinstein RS, Altman R, et al. Comparative study of alendronate vs etidronate for the treatment of Paget disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
41. Reid I, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized placebo-controlled trial. Am J Med. 1996;101:341-348.
42. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone. 1994;15:415-417.
43. Peter CP, Kindt MV, Majka JA. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci. 1998;43:1009-1015.
44. Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci. 1998;43:1998-2002.
45. Hooper M, Faustino A, Reid IR, et al. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. Osteoporos Int. 2009;20: 141-150.
46. Miller PD, Adachi JD, Brown JP, et al. Risedronate vs etidronate: Durable remission with only two months of 30 mg risedronate. J Bone Miner Res. 1997;12:S269.
47. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A prospective, multicenter, randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget disease of bone. Am J Med. 1999;106:513-520.
48. Frijlink WB, Bijvoet OLM, teVelde J, Heynen G. Treatment of Paget disease with 3-amino-1-hydroxypropylidene-l,l-biphosphonate (APD). Lancet. 1979;1:799-803.
49. Walsh JP, Attewell R, Stuckey BGA, et al. Treatment of Paget disease of bone: A survey of clinical practice in Australia. Bone. 2008;42: 1219-1225.
50. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ. 1987;295:1301-1305.
51. Joshua F, Epstein M, Major G. Bisphosphonate Resistance in Paget's disease of Bone. Arthritis Rheum. 2003;48:2321-2323.
52. Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget disease of bone. Bone. 2004;34:747-754.
53. Wimalawansa SJ, Gunasekara RD. Pamidronate is effective for Paget disease of bone refractory to conventional therapy. Calcif Tissue Int. 1993;53:237-241.
54. Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, et al. Clinical, biochemical, hematologic, and radiographic responses in Paget disease following intravenous pamidronate disodium: a 2-year study. Bone. 1996;19:387-394.
55. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Effect of multiple intravenous pamidronate courses in Paget disease of bone. Rev Rhum. 1999;66:467-476.
56. Gallacher SJ, Boyce BF, Patel U, Jenkins A, Ralston SH, Boyle IT. Clinical experience with pamidronate in the treatment of Paget disease of bone. Ann Rheum Dis. 1991;50:930-933.
57. Stone MD, Hawthorne AB, Kerr D, Webster G, Hosking DJ. Treatment of Paget disease with intermittent low-dose infusions of disodium pamidronate (APD). J Bone Miner Res. 1990;5:1231-1235.
58. Bombassei GJ, Yocono M, Raisz LG. Effects of intravenous pamidronate therapy on Paget disease of bone. Am J Med Sci. 1994;308:226-233.
59. Stuckey BG, Gutteridge DH, Stewart GO, et al. Intravenous pamidronate in Paget disease - response is dependent on radiographic and biochemical severity. Semin Arthritis Rheum. 1994;23:286.
60. Cundy T, Wattie D, King AR. High-dose pamidronate in the management of resistant Paget disease. Calcif Tissue Int. 1996;58:6-8.
61. Gutteridge DH, Ward LC, Stewart GO, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res. 1999;14:79-84.
62. Lyles KW. What is "resistance" in Paget disease of bone? Arthritis Rheum. 2003;48:2097-2099.
63. Merlotti D, Gennari L, Martini G, et al. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J Bone Miner Res. 2007;22:1510-1517.
64. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF. Mineralization defects with pamidronate therapy for Paget's disease. Lancet. 1993;342:1459-1460.
65. Boyce BF, Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT. Mineralization defects after pamidronate for Paget disease. Lancet. 1994;343;1231-1232.
66. Buckler HM, Mercer SJ, Davison CE, Hollis S, Richardson PC, Anderson DG. Evaluation of adverse experiences related to pamidronate infusion in Paget disease of bone. Ann Rheum Dis. 1998;57:572.
67. Nicolin V, Bareggi R, Baldini G, Bortul R, Martinelli B, Narducci P. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures. Acta Histochem. 2007;109:397-402.
68. Spreafico A, Frediani B, Capperucci C, et al. Anabolic effects and inhibition of interleukin 6 production induced by neridronate on human osteoblasts. Reumatismo. 2006;58:288-300.
69. Braga V, Gatti D, Colapietro F, et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone. 2003;33:342-345.
70. D'Eufemia P, Finocchiaro R, Celli M, et al. High levels of serum prostaglandin e2 in children with osteogenesis imperfecta are reduced by neridronate treatment. Pediatr Res. 2008;63:203-206.
71. Magno C, Inastasi G, Morabito N, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol. 2005;47:575-581.
72. Pittari G, Costi D, Raballo M, Maulucci L, Baroni MC, Mangoni M. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma. Acta Biomed. 2006;77:81-84.
73. Atkins RM, Yates AJ, Gray RE, et al. Aminohexane disphosphonate in the treatment of Paget disease of bone. J Bone Miner Res. 1987;2: 273-279.
74. Delmas P, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane bisphosphonate in patients with Paget disease of bone resistant to sodium etidronate. Am J Med. 1987;83:276-282.
75. McCloskey EV, Yates AJP, Beneton MNC, Galloway G, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 1987;8:S35-S41.
76. Coulton LA, Preston CJ, Couch M, Kanis JA. An evaluation of serum osteocalcin in Paget disease of bone and its response to diphosphonate treatment. Arthrit Rheum. 1988;31:1142-1147.
77. Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone. 1998;23:543-548.
78. Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol. 2002;20:55-58.
79. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone. 2006;38:617-627.
80. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.
81. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Dev Res. 2002;55:210-224.
82. Body JJ. Clinical research update: zoledronate. Cancer. 1997;80: 1699-1701.
83. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
84. Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol. 1997;80:225-230.
85. Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget disease of bone. Calcif Tissue Int. 1997;60:415-418.
86. Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget disease of bone: a placebo-controlled, dose-ranging study. Bone. 1999;24:81S-85S.
87. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget disease. N Engl J Med. 2005;353:898-908.
88. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142-148.
89. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget disease of bone. Bone. 2001;28:461-464.
90. Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol. 1999;26:1972-1982.
91. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
92. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.
93. Thompson K, Rogers MJ. Bisphosphonates and γ, δ T-cells: new insights into old drugs. BoneKEy-Osteovision. 2006;3:5-13.
94. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma-delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004;19:278-288.
95. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007; 6:663-672.
96. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281-289.
97. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
98. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22: 1479-1489.
99. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761.
100. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008;139:32-40.
101. Ott SM. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med. 2004;351:190-192.
102. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
103. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349: 457-463.
104. Reid IR. Zoledronate: Efficacy and Safety. J Bone Miner Res. 2006;21:83-87.
105. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53-62.
106. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122: S22-S32.
107. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360:89-90.
108. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
109. Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int. 2007;80:1-9.
110. Redden JF, Dixon J, Vennart W, Hosking DJ. Management of fissure fractures in Paget's disease. Int Orthop. 1981;5:103-106.
111. Kaplan FS. Surgical management of Paget's disease. J Bone Miner Res. 1999;14:34-38.
112. Sharma H, MacDu. E, Jane MJ, Reid R. Sarcomatous change in the Pagetoid tibiae. Int Orthop. 2005;29:319-325.
113. Mankin HJ, Hornicek FJ. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res. 2005;438:97-102.
114. Mayilvahanan N, Bose JC, Paraskumar M, et al. Paget's sarcoma: limb salvage by custom mega prosthesis: four case reports. J Orthop Surg (Hong Kong). 2004;12:243-247.
115. Devogelaer JP, Bergmann P, Body JJ, et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int. 2008;19:1109-1117.